Correlation Between SPDR Barclays and Maat Pharma

Can any of the company-specific risk be diversified away by investing in both SPDR Barclays and Maat Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SPDR Barclays and Maat Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SPDR Barclays Euro and Maat Pharma SA, you can compare the effects of market volatilities on SPDR Barclays and Maat Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SPDR Barclays with a short position of Maat Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of SPDR Barclays and Maat Pharma.

Diversification Opportunities for SPDR Barclays and Maat Pharma

0.33

Correlation Coefficient

SPDR Barclays  Maat Pharma

Weak diversification

The 3 months correlation between SPDR and Maat is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding SPDR Barclays Euro and Maat Pharma SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Maat Pharma SA and SPDR Barclays is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SPDR Barclays Euro are associated (or correlated) with Maat Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Maat Pharma SA has no effect on the direction of SPDR Barclays i.e., SPDR Barclays and Maat Pharma go up and down completely randomly.

Pair Corralation between SPDR Barclays and Maat Pharma

Assuming the 90 days trading horizon SPDR Barclays Euro is expected to under-perform the Maat Pharma. But the etf apears to be less risky and, when comparing its historical volatility, SPDR Barclays Euro is 25.65 times less risky than Maat Pharma. The etf trades about -0.1 of its potential returns per unit of risk. The Maat Pharma SA is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  798.00  in Maat Pharma SA on October 27, 2024 and sell it today you would earn a total of  4.00  from holding Maat Pharma SA or generate 0.5% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

SPDR Barclays Euro  vs.  Maat Pharma SA

SPDR Barclays Euro

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days SPDR Barclays Euro has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, SPDR Barclays is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Maat Pharma SA

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Maat Pharma SA are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Maat Pharma may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with SPDR Barclays and Maat Pharma

The main advantage of trading using opposite SPDR Barclays and Maat Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SPDR Barclays position performs unexpectedly, Maat Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Maat Pharma will offset losses from the drop in Maat Pharma's long position.

The idea behind SPDR Barclays Euro and Maat Pharma SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.